April 30, 2025
| Trial | REFINE-Lung |
|---|---|
| Cancer Type | Lung Cancer |
| Hospital(s) | Altnagelvin Hospital |
| Information | A randomised open-label phase III trial of Reduced Frequency pembrolizumab immuNothErapy for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm frequency-response optimisation design |
 |
Click Here to view Cancer Research UK trial summary |